Evolution of the Average Target: Bicycle Therapeutics plc

Evolution of the Average Target - Bicycle Therapeutics plc

Evolution of the Target Price: Bicycle Therapeutics plc

Evolution of the Target Price - Bicycle Therapeutics plc

Changes in Analyst Recommendations: Bicycle Therapeutics plc

435ab51ac33eee3.zjKj__kRilA8oMTFdJWYvJUR6t1SRBbXf-I8j46YE2c.9wPJsZdD2xxy7_yNDP3eifZ4potrdX2iKNdM6uH6IAaMXpKei0fPEW3kgQ~48085472261559fadae1652572f3f20d
31/07 Oppenheimer Adjusts Price Target on Bicycle Therapeutics to $11 From $36, Maintains Outperform Rating MT
18/03 Oppenheimer Adjusts Bicycle Therapeutics PT to $36 From $44, Maintains Outperform Rating MT
18/03 RBC Cuts Price Target on Bicycle Therapeutics to $7 From $11, Keeps Sector Perform, Speculative Risk MT
31/25/31 RBC Downgrades Bicycle Therapeutics to Sector Perform From Outperform, Cuts Price Target to $11 From $27, Keeps Speculative Risk MT
11/25/11 Oppenheimer Adjusts Price Target on Bicycle Therapeutics to $44 From $48, Maintains Outperform Rating MT
11/25/11 RBC Capital Adjusts Price Target on Bicycle Therapeutics to $27 From $25, Maintains Outperform Speculative Risk Rating MT
17/25/17 RBC Cuts Price Target on Bicycle Therapeutics to $25 From $32, Keeps Outperform, Speculative Risk MT
02/25/02 RBC Cuts Price Target on Bicycle Therapeutics to $32 From $35, Keeps Outperform, Speculative Risk MT
16/24/16 B. Riley Adjusts Price Target on Bicycle Therapeutics to $17 From $28, Keeps Neutral Rating MT
08/24/08 Stephens Starts Bicycle Therapeutics With Equalweight Rating MT
06/24/06 RBC Initiates Bicycle Therapeutics at Outperform, Speculative Risk With $35 Price Target MT
07/24/07 B. Riley Downgrades Bicycle Therapeutics to Neutral From Buy, Cuts Price Target to $28 From $33 MT
21/24/21 HC Wainwright Adjusts Bicycle Therapeutics Price Target to $55 From $57, Maintains Buy Rating MT
20/23/20 JMP Securities Cuts Bicycle Therapeutics Price Target to $32 From $44, Maintains Market Outperform Rating MT
03/23/03 Morgan Stanley Cuts Price Target on Bicycle Therapeutics to $40 From $42, Maintains Equal-Weight Rating MT
12/23/12 B. Riley Upgrades Bicycle Therapeutics to Buy From Neutral After Announced Alignment With US FDA on Phase 2/3 Registrational Trial for BT8009 for Metastatic Bladder Cancer; PT is $33 MT
04/23/04 Oppenheimer Adjusts Bicycle Therapeutics Price Target to $48 From $55, Maintains Outperform Rating MT
04/23/04 JMP Securities Adjusts Price Target on Bicycle Therapeutics to $44 From $46, Maintains Outperform Rating MT
04/23/04 Needham Adjusts Price Target on Bicycle Therapeutics to $46 From $48, Maintains Buy Rating MT
05/23/05 Needham Adjusts Price Target on Bicycle Therapeutics to $64 From $67, Maintains Buy Rating MT
01/23/01 Needham Adjusts Price Target on Bicycle Therapeutics to $67 From $72, Keeps Buy Rating MT
05/23/05 EF Hutton Initiates Bicycle Therapeutics at Buy, $55 Price Target MT
09/22/09 JMP Securities Adjusts Price Target on Bicycle Therapeutics to $46 From $70, Maintains Market Outperform Rating MT
12/22/12 Morgan Stanley Lowers Price Target on Bicycle Therapeutics to $45 From $60, Keeps Equalweight Rating MT
31/22/31 Cowen Initiates Coverage on Bicycle Therapeutics With Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+167.61%
+32.59%
+28.07%
+10.26%
+8.34%
+15.58%
+38.43%
+38.53%
+31.23%
+4.99%
Average +37.56%
Weighted average by Cap. +23.44%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.550USD
Average target price
9.500USD
Spread / Average Target
+167.61%
High Price Target
14.00USD
Spread / Highest target
+294.37%
Low Price Target
5.000USD
Spread / Lowest Target
+40.85%

Analyst Consensus Detail

Analyst consensus - Bicycle Therapeutics plc

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Bicycle Therapeutics plc
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bicycle Therapeutics plc
  1. Stock Market
  2. Stocks
  3. BCYC Stock
  4. Consensus Bicycle Therapeutics plc